Cargando…

Nanocarriers of Fe(3)O(4) as a Novel Method for Delivery of the Antineoplastic Agent Doxorubicin Into HeLa Cells in vitro

Here we report the synthesis and in vitro characterization of a redox-sensitive, magnetically inducible nanoparticle carrier system based on the doxorubicin (DOX) drug delivery model. Each quantal nanocarrier unit consists of a magnetite Fe(3)O(4) nanoparticle core that is further encapsulated in se...

Descripción completa

Detalles Bibliográficos
Autores principales: Xia, Kun-kun, Lyu, Yong, Yuan, Wei-tang, Wang, Gui-xian, Stratton, Harrison, Zhang, Shui-jun, Wu, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6499231/
https://www.ncbi.nlm.nih.gov/pubmed/31110964
http://dx.doi.org/10.3389/fonc.2019.00250
_version_ 1783415766469574656
author Xia, Kun-kun
Lyu, Yong
Yuan, Wei-tang
Wang, Gui-xian
Stratton, Harrison
Zhang, Shui-jun
Wu, Jie
author_facet Xia, Kun-kun
Lyu, Yong
Yuan, Wei-tang
Wang, Gui-xian
Stratton, Harrison
Zhang, Shui-jun
Wu, Jie
author_sort Xia, Kun-kun
collection PubMed
description Here we report the synthesis and in vitro characterization of a redox-sensitive, magnetically inducible nanoparticle carrier system based on the doxorubicin (DOX) drug delivery model. Each quantal nanocarrier unit consists of a magnetite Fe(3)O(4) nanoparticle core that is further encapsulated in self-assembled micelles of the redox-responsive polyethylene glycol derivative, DSPE-SS-mPEG. The nanocarrier system was prepared using a combination of ultrasonication and dialysis to produce the microenvironment sensitive delivery system. The final synthesized and DOX-loaded magnetic nanocarriers had an average size of ~150 nm when assembled with a 6.9% DOX payload. The release rate of DOX from these redox-responsive magnetic nanocarriers was shown to be accelerated in vitro when in the presence of glutathione (GSH). Furthermore, we demonstrated that more redox-responsive magnetic nanocarriers could be taken up by HeLa cells when a local magnetic field was applied. Once internalized within a cell, the micelles of the outer nanocarrier complex were broken down in the presence of higher concentrations of GSH, which accelerated the release of DOX. This produces a particle with dual operating characteristics that can be controlled via a specific cellular environment coupled with an exogenously applied signal in the form of a magnetic field triggering release.
format Online
Article
Text
id pubmed-6499231
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-64992312019-05-20 Nanocarriers of Fe(3)O(4) as a Novel Method for Delivery of the Antineoplastic Agent Doxorubicin Into HeLa Cells in vitro Xia, Kun-kun Lyu, Yong Yuan, Wei-tang Wang, Gui-xian Stratton, Harrison Zhang, Shui-jun Wu, Jie Front Oncol Oncology Here we report the synthesis and in vitro characterization of a redox-sensitive, magnetically inducible nanoparticle carrier system based on the doxorubicin (DOX) drug delivery model. Each quantal nanocarrier unit consists of a magnetite Fe(3)O(4) nanoparticle core that is further encapsulated in self-assembled micelles of the redox-responsive polyethylene glycol derivative, DSPE-SS-mPEG. The nanocarrier system was prepared using a combination of ultrasonication and dialysis to produce the microenvironment sensitive delivery system. The final synthesized and DOX-loaded magnetic nanocarriers had an average size of ~150 nm when assembled with a 6.9% DOX payload. The release rate of DOX from these redox-responsive magnetic nanocarriers was shown to be accelerated in vitro when in the presence of glutathione (GSH). Furthermore, we demonstrated that more redox-responsive magnetic nanocarriers could be taken up by HeLa cells when a local magnetic field was applied. Once internalized within a cell, the micelles of the outer nanocarrier complex were broken down in the presence of higher concentrations of GSH, which accelerated the release of DOX. This produces a particle with dual operating characteristics that can be controlled via a specific cellular environment coupled with an exogenously applied signal in the form of a magnetic field triggering release. Frontiers Media S.A. 2019-04-10 /pmc/articles/PMC6499231/ /pubmed/31110964 http://dx.doi.org/10.3389/fonc.2019.00250 Text en Copyright © 2019 Xia, Lyu, Yuan, Wang, Stratton, Zhang and Wu. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Xia, Kun-kun
Lyu, Yong
Yuan, Wei-tang
Wang, Gui-xian
Stratton, Harrison
Zhang, Shui-jun
Wu, Jie
Nanocarriers of Fe(3)O(4) as a Novel Method for Delivery of the Antineoplastic Agent Doxorubicin Into HeLa Cells in vitro
title Nanocarriers of Fe(3)O(4) as a Novel Method for Delivery of the Antineoplastic Agent Doxorubicin Into HeLa Cells in vitro
title_full Nanocarriers of Fe(3)O(4) as a Novel Method for Delivery of the Antineoplastic Agent Doxorubicin Into HeLa Cells in vitro
title_fullStr Nanocarriers of Fe(3)O(4) as a Novel Method for Delivery of the Antineoplastic Agent Doxorubicin Into HeLa Cells in vitro
title_full_unstemmed Nanocarriers of Fe(3)O(4) as a Novel Method for Delivery of the Antineoplastic Agent Doxorubicin Into HeLa Cells in vitro
title_short Nanocarriers of Fe(3)O(4) as a Novel Method for Delivery of the Antineoplastic Agent Doxorubicin Into HeLa Cells in vitro
title_sort nanocarriers of fe(3)o(4) as a novel method for delivery of the antineoplastic agent doxorubicin into hela cells in vitro
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6499231/
https://www.ncbi.nlm.nih.gov/pubmed/31110964
http://dx.doi.org/10.3389/fonc.2019.00250
work_keys_str_mv AT xiakunkun nanocarriersoffe3o4asanovelmethodfordeliveryoftheantineoplasticagentdoxorubicinintohelacellsinvitro
AT lyuyong nanocarriersoffe3o4asanovelmethodfordeliveryoftheantineoplasticagentdoxorubicinintohelacellsinvitro
AT yuanweitang nanocarriersoffe3o4asanovelmethodfordeliveryoftheantineoplasticagentdoxorubicinintohelacellsinvitro
AT wangguixian nanocarriersoffe3o4asanovelmethodfordeliveryoftheantineoplasticagentdoxorubicinintohelacellsinvitro
AT strattonharrison nanocarriersoffe3o4asanovelmethodfordeliveryoftheantineoplasticagentdoxorubicinintohelacellsinvitro
AT zhangshuijun nanocarriersoffe3o4asanovelmethodfordeliveryoftheantineoplasticagentdoxorubicinintohelacellsinvitro
AT wujie nanocarriersoffe3o4asanovelmethodfordeliveryoftheantineoplasticagentdoxorubicinintohelacellsinvitro